March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Remission Of Intermediate Uveitis: Rate And Predictive Factors
Author Affiliations & Notes
  • Dina Gewaily
    Ophthalmology, Ophthalmology,
    Scheie Eye Inst/Univ of Pennsylvania, Philadelphia, Pennsylvania
  • Craig Newcomb
    Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, Univ of Pennsylvania, Philadelphia, Pennsylvania
  • Grace Levy-Clarke
    Tampa Uveitis, Tampa, Florida
  • Robert B. Nussenblatt
    Laboratory of Immunology, National Eye Inst/NIH, Bethesda, Maryland
  • James T. Rosenbaum
    Ophthalmology, Ophthalmology,
    Casey Eye Inst/OHSU, Portland, Oregon
  • Eric B. Suhler
    Ophthal-Biostatistics & Epidemiol, Uveitis Clinic/Portland VAMC,
    Casey Eye Inst/OHSU, Portland, Oregon
  • Jennifer E. Thorne
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, Maryland
  • C Stephen Foster
    Ophthalmology, Ocular Immunol & Uveitis Fndtn, Cambridge, Massachusetts
  • Douglas A. Jabs
    Ophthalmology, Mount Sinai School of Medicine, New York, New York
  • John H. Kempen
    Ophthal-Biostatistics & Epidemiol, Uveitis Clinic/Portland VAMC,
    Scheie Eye Inst/Univ of Pennsylvania, Philadelphia, Pennsylvania
  • Footnotes
    Commercial Relationships  Dina Gewaily, None; Craig Newcomb, None; Grace Levy-Clarke, None; Robert B. Nussenblatt, None; James T. Rosenbaum, None; Eric B. Suhler, None; Jennifer E. Thorne, None; C Stephen Foster, None; Douglas A. Jabs, None; John H. Kempen, None
  • Footnotes
    Support  NIH/NEI Grant EY014943, Research to Prevent Blindness, Mackall Foundation, NEI Intramural Funds, Dept of Veterans Affairs
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 5478. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Dina Gewaily, Craig Newcomb, Grace Levy-Clarke, Robert B. Nussenblatt, James T. Rosenbaum, Eric B. Suhler, Jennifer E. Thorne, C Stephen Foster, Douglas A. Jabs, John H. Kempen; Remission Of Intermediate Uveitis: Rate And Predictive Factors. Invest. Ophthalmol. Vis. Sci. 2012;53(14):5478.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To evaluate the incidence of remission among patients with intermediate uveitis, as well as factors potentially predictive of remission.

 
Methods:
 

A retrospective cohort study using standardized chart review data was performed. Patients with primary non-infectious intermediate uveitis presenting to 1 of 4 academic ocular inflammation subspecialty practices were included. Remission of intermediate uveitis was the primary outcome, defined as lack of inflammatory activity at ≥2 visits spanning ≥90 days in the absence of any anti-inflammatory medications. Factors potentially predictive of intermediate uveitis remission were evaluated using survival analysis, including Cox multiple regression.

 
Results:
 

We identified 434 patients with intermediate uveitis who were followed for over 925 person-years, during which time the incidence rate of intermediate uveitis remission was 9.4 per 100 person-year (95% confidence interval, 7.5-11.6). The majority (82%) of patients experienced bilateral intermediate uveitis at least once during their clinical course. There was a low frequency of associated systemic disease diagnosed. Factors predictive of disease remission included prior pars plana vitrectomy (PPV) (20.9 per 100 person-years, HR (vs. no PPV)=2.71; 95% CI, 1.64-4.47; Figure) and diagnosis of intermediate uveitis within the last year (34.1 per 100 person-years, HR (vs. diagnosis >5 years ago)=4.12, 95% CI: 1.89-8.95).

 
Conclusions:
 

Our results suggest that intermediate uveitis is a chronic disease with an overall low rate of remission. Patients presenting early in their disease course are more likely to gain remission than patients who already have had ongoing activity without remission for several years at the time of initial presentation. With regards to management, pars plana vitrectomy was associated with increased probability of remission, but a large number of cases that received vitrectomy continued to have ongoing disease activity.  

 
Keywords: uveitis-clinical/animal model • clinical (human) or epidemiologic studies: prevalence/incidence • clinical (human) or epidemiologic studies: risk factor assessment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×